hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06375525, orgStudyIdInfo id: SHEBA-15-2635-SMC, briefTitle: Clinical Trial: The Efficacy of Janssen's Icon Application (App) in Improving Adherence to Treatment With Stimulant Medications in Children With Attention Deficit/Hyperactivity Disorder, acronym: App ADHD, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-11, primaryCompletionDateStruct date: 2017-08, completionDateStruct date: 2017-08, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Prof. Doron Gothelf MD, class: OTHER_GOV, descriptionModule briefSummary: The overarching aim of the study is to assess the efficacy of Janssen's icon Application (App), a digital tool designed to improve adherence to medication treatment in children with ADHD.Our specific hypotheses are:1. In children receiving medication for ADHD those provided with the App tool will be more adherent to treatment than children treated as usual (i.e., not provided with the App tool).2. Adherent patients will show greater improvement of ADHD symptoms and related dysfunction., conditionsModule conditions: Children Aged 6-18 Years With the Diagnosis of ADHD, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ACTUAL, armsInterventionsModule interventions name: Janssen's icon Application (App), outcomesModule primaryOutcomes measure: Attention Module of the Kiddie-SADS questionniare, secondaryOutcomes measure: MINI-KID, otherOutcomes measure: ADHD-Rating Scale Questionnaire (ADHD-RS), otherOutcomes measure: Clinical Global Impression Scale (CGI), otherOutcomes measure: the Barkley Side Effects Rating Scale, otherOutcomes measure: Drug accountability by reviewing the completed medication logs, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: ADHD Medical Clinic, Child and Adolescent Psychiatry Unit, Sheba Medical Center, city: Ramat-Gan, country: Israel, geoPoint lat: 32.08227, lon: 34.81065, hasResults: False
protocolSection identificationModule nctId: NCT06375499, orgStudyIdInfo id: LT2769-004, briefTitle: Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2025-04-28, completionDateStruct date: 2025-04-28, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Laboratoires Thea, class: INDUSTRY, descriptionModule briefSummary: The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in the study eye at the D36 visit.The investigation is defined as a post-market stage. The clinical investigation design is confirmatory., conditionsModule conditions: Dry Eye Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: T2769, interventions name: Hylo-Forte®, outcomesModule primaryOutcomes measure: To demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of total ocular surface staining (Oxford score)., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06375486, orgStudyIdInfo id: AK112-IIT-TianjinCIH-LHK, briefTitle: Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2025-03-14, completionDateStruct date: 2026-06-15, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China. The primary objective is to evaluate the safety and efficacy of AK112 (a dual-specific antibody against PD-1/VEGF) in combination with hepatic arterial infusion chemotherapy (HAIC) for the treatment of unresectable hepatocellular carcinoma.All enrolled subjects will receive AK112 (20mg/kg Q3W) combined with HAIC (utilizing the FOLFOX chemotherapy regimen) until the investigator determines no further clinical benefit (based on RECIST v1.1 imaging evaluation and clinical assessment), intolerable toxicity, completion of 24 months of treatment, or meeting other criteria for treatment discontinuation as outlined in the protocol, whichever occurs first., conditionsModule conditions: Hepatocellular Carcinoma Non-resectable, conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, outcomesModule primaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Progress Free Survival （PFS）, secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Adverse Events（AEs）, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tianjin Cancer Hospital Airport Hospital, status: RECRUITING, city: Tianjin, state: Tianjin, zip: 300308, country: China, contacts name: Huikai Li, Doctor, role: CONTACT, phone: 18622228639, email: tjchlhk@126.com, contacts name: Yang Liu, MD, role: CONTACT, phone: 17694950696, email: tjchlhk@126.com, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06375473, orgStudyIdInfo id: MA-PC-RWS-011, briefTitle: Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients, acronym: MA-PC-RWS-011, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-19, primaryCompletionDateStruct date: 2027-04-19, completionDateStruct date: 2027-04-19, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen., conditionsModule conditions: Pancreatic Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3000, type: ESTIMATED, armsInterventionsModule interventions name: Irinotecan liposome II combination therapy regimen, outcomesModule primaryOutcomes measure: rwTEAE, secondaryOutcomes measure: OS, secondaryOutcomes measure: PFS, secondaryOutcomes measure: ORR, secondaryOutcomes measure: TTP, secondaryOutcomes measure: DCR, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, city: Beijing, state: Beijing, zip: 100730, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06375434, orgStudyIdInfo id: 20240101-01, briefTitle: Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer, acronym: GMRSC-LARC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2024-08-15, completionDateStruct date: 2024-08-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Jing-kun Liu, class: OTHER, descriptionModule briefSummary: The purpose of this process is to clarify the characteristics of gut microbiota changes in patients with locally advanced rectal cancer undergoing preoperative neoadjuvant treatment, and to identify key bacterial species closely related to sensitivity to radiotherapy. This aims to elucidate the mechanism linking gut microbiome dysbiosis with radiotherapy sensitivity, thereby providing new combined treatment strategies to enhance the efficacy of radiotherapy., conditionsModule conditions: Locally Advanced Rectal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Diameter of tumor, secondaryOutcomes measure: Change in Gut Microbiota Composition, secondaryOutcomes measure: Change in Plasma metabolites, otherOutcomes measure: Five-year survival rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06375421, orgStudyIdInfo id: GR018280, briefTitle: Pilot and Feasibility of MEMI for Chronic Traumatic Brain Injury, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-03, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Vanderbilt University Medical Center, class: OTHER, descriptionModule briefSummary: This is a pilot and feasibility study for a mobile phone-delivered intervention for memory, called MEMI (memory ecological momentary intervention), that was designed to support adults with chronic traumatic brain injury with their memory. The goal of the study is to examine the feasibility and acceptability of MEMI and to assess preliminary efficacy as to whether technology-delivered spaced memory retrieval opportunities improve memory in people with and without a history of chronic traumatic brain injury., conditionsModule conditions: Traumatic Brain Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: The order of conditions and the order of word list presentation will be counterbalanced. The order of condition/word list combination will be pre-determined, and participants will be assigned to the next available combination based on when they join the study (i.e., a counterbalanced within-person crossover design)., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval, interventions name: Blocked Retrieval, outcomesModule primaryOutcomes measure: Acceptability, primaryOutcomes measure: Feasibility (Engagement), secondaryOutcomes measure: Free Recall of Word Forms, secondaryOutcomes measure: Cued Recall of Word Forms, secondaryOutcomes measure: Cued Recall of Word Meanings, otherOutcomes measure: Number of Spatial Contexts, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Vanderbilt University Medical Center, city: Nashville, state: Tennessee, zip: 37203, country: United States, geoPoint lat: 36.16589, lon: -86.78444, hasResults: False
protocolSection identificationModule nctId: NCT06375408, orgStudyIdInfo id: KS2022212, briefTitle: Transcranial Alternating Current Stimulation Prevents Delirium in Patients With Subarachnoid Hemorrhage, acronym: TACS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-24, primaryCompletionDateStruct date: 2026-02-24, completionDateStruct date: 2026-03-24, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn about using the latest transcranial alternating current stimulation (tACS) to reduce the incidence of delirium in patients with subarachnoid hemorrhage. The main question it aims to answer is:• To evaluate the effect of tACS on reducing delirium in patients with subarachnoid hemorrhage.Participants will treated with real tACS or sham tACS. Researchers will mainly compare the two groups to see if patients' delirium will reduce by using tACS., conditionsModule conditions: Subarachnoid Hemorrhage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, maskingDescription: The random number table method was used for randomization, and the envelope method was used for randomization. The random serial number was stored in an airtight envelope, an envelope was opened when a patient was admitted., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: Real transcranial alternating electrical stimulation, interventions name: Sham transcranial alternating electrical stimulation, outcomesModule primaryOutcomes measure: Incidence of delirium, secondaryOutcomes measure: Sleep quality score, secondaryOutcomes measure: Anxiety score, secondaryOutcomes measure: Duration of delirium, secondaryOutcomes measure: Cognitive function score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xuanwu Hospital Capital Medical University, status: RECRUITING, city: Beijing, state: Beijing, zip: 100053, country: China, contacts name: Jun Wang, role: CONTACT, phone: 18612583695, email: wangj229@126.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06375395, orgStudyIdInfo id: Memory Updating Tasks, briefTitle: Boosting The Intervention Effect of Negative Memory Through tACS Stimulation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2024-12-15, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, collaborators name: Beijing Normal University, descriptionModule briefSummary: The objectives of this study include: 1) investigating the impact of negative memory substitution on an individual's other intellectual memories (i.e., neutral memories) and the underlying neurocognitive mechanisms; 2) investigating the memory enhancement effect resulting from retrieval practice associated with memory substitution intervention along with an examination of the neurocognitive mechanisms responsible for this enhancement., conditionsModule conditions: Seizures, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Active tACS Device, interventions name: Sham tACS Device, outcomesModule primaryOutcomes measure: Negative memory retention, secondaryOutcomes measure: The negative emotional intensity of negative memory, secondaryOutcomes measure: The retention of associated neutral memories as assesses by the proportions of responses of correctly choosing picture category of B picture (A-Bneu) in last A-B paired associate memory test, secondaryOutcomes measure: The negative emotional intensity of neutral memory, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06375382, orgStudyIdInfo id: ZYS2024-01, briefTitle: Effects of Acupuncture on Abdominal Pain-related Intestinal Flora in Patients With Crohn's Disease, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-03-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Shanghai Institute of Acupuncture, Moxibustion and Meridian, class: OTHER, descriptionModule briefSummary: Crohn's disease is an intestinal inflammatory disease, causing abdominal pain, diarrhea and other symptoms. The intestinal flora disorder is closely related to the occurrence and development of Crohn's disease. Acupuncture can induce remission of Crohn's disease during mild to moderate active period, improve clinical symptoms such as abdominal pain. This study is to screen the intestinal bacteria related to abdominal pain in CD, and explore the effects of acupuncture on the intestinal flora related to abdominal pain in CD patients., conditionsModule conditions: Crohn Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 64, type: ACTUAL, armsInterventionsModule interventions name: acupuncture, interventions name: Sham acupuncture, outcomesModule primaryOutcomes measure: Abdominal pain remission rate, secondaryOutcomes measure: Crohn's disease activity index （CDAI）, secondaryOutcomes measure: Hospital anxiety and depression scale (HADS), secondaryOutcomes measure: Inflammatory bowel disease questionnaire (IBDQ), secondaryOutcomes measure: Safety evaluation (number of participants with abnormal routine blood tests), secondaryOutcomes measure: Safety evaluation (number of participants with abnormal Liver function tests), secondaryOutcomes measure: Safety evaluation (number of participants with abnormal Renal function tests), otherOutcomes measure: Gut microbiota composition structure and function, otherOutcomes measure: Correlation between changes in relative abundance of gut microbes and abdominal pain, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Institute of Acupuncture, Moxibustion and Meridian, city: Shanghai, zip: 200000, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06375356, orgStudyIdInfo id: 75119, briefTitle: Stronger: Muscle Strengthening for Menopause, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: Menopause is a period of time with increased risk for muscle and bone loss. Very few people strength train regularly at least 2 times per week, and commonly reported barriers include inadequate time and resources, worries of safety, inadequate knowledge base of what moves to do and how to do them. Menopause-aged women may report unique barriers - or perceived facilitators - to strength training. This pilot study will develop and test the feasibility and acceptability of an at-home, band-based, expert-supported strength training intervention., conditionsModule conditions: Resistance Training, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Resistance Training, outcomesModule primaryOutcomes measure: number of strength exercises the participant logged over the intervention, primaryOutcomes measure: Liking of the intervention, secondaryOutcomes measure: Number of participants completing post 3 month measure / those randomized and consented, secondaryOutcomes measure: Change in total seconds a participant can remain in a wall sit, secondaryOutcomes measure: Change in number of full body weight squats in 60 seconds, eligibilityModule sex: FEMALE, minimumAge: 35 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stanford University School of Medicine, city: Stanford, state: California, zip: 94305-7240, country: United States, geoPoint lat: 37.42411, lon: -122.16608, hasResults: False
protocolSection identificationModule nctId: NCT06375343, orgStudyIdInfo id: SOPH240-0923/I, briefTitle: Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-30, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Laboratorios Sophia S.A de C.V., class: INDUSTRY, descriptionModule briefSummary: This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®., conditionsModule conditions: Dry Eye Disease, conditions: Dry Eye Sensation, conditions: Ocular Surface Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Phase I, controlled, comparative, single-blind, single-center, comparative clinical trial., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: PRO-240, interventions name: Optive®, outcomesModule primaryOutcomes measure: Incidence of unexpected adverse events related to the interventions, secondaryOutcomes measure: Changes in the Ocular Comfort Index score, secondaryOutcomes measure: Adherence to treatment (adherence) Adherence to treatment (adherence), secondaryOutcomes measure: Changes in Best Corrected Visual Acuity (BCVA), secondaryOutcomes measure: Changes in tear film breakup time, secondaryOutcomes measure: Changes in intraocular pressure (IOP), secondaryOutcomes measure: Changes in the integrity of the ocular surface (fluorescein staining), secondaryOutcomes measure: Changes in lissamine green staining of the conjunctival surface, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False